Market Overview

Mylan: There's No Logic In The Teva Merger Rumor

Related MYL
Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe
Watch These 7 Huge Put Purchases In Wednesday Trade
Related TEVA
AstraZeneca CEO Rumor Reportedly Ends, Shares Rise
The Market In 5 Minutes
The Vetr community has upgraded $TEVA to 3.5-Stars. (Vetr)

Mylan NV (NASDAQ: MYL) tried to pour cold water on a report Friday it might be acquired by Teva Pharmaceutical Industries Ltd (NYSE: TEVA).

But Mylan jumped more than 4 percent recently to $69.70.

Mylan Executive Chairman Robert J. Coury said a merger with Teva would be "without sound industrial logic or cultural fit."

Coury added that such a deal would probably be blocked by antitrust regulators.

Related Link: Why The Mylan 'Love Triangle' Could Benefit Investors

If any offer materialized, however, Coury said Mylan's board "would carefully consider it," acting in the best interests of Mylan and its shareholders.

Citing unnamed sources, Bloomberg said earlier that Teva is deliberating whether to make an offer.

Mylan's April 8 unsolicited $28.9 billion offer for Perrigo Co. (NYSE: PRGO) is viewed by some investors as an incentive for Teva to make a bid.

Posted-In: News M&A


Related Articles (MYL + PRGO)

View Comments and Join the Discussion!